title: Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
authors.forename: J
authors.initials: J
authors.lastname: Sanders
authors.forename: B
authors.initials: B
authors.lastname: Crawford
authors.forename: J
authors.initials: J
authors.lastname: Gibson
authors.forename: P
authors.initials: P
authors.lastname: Joy Ho
authors.forename: H
authors.initials: H
authors.lastname: Iland
authors.forename: D
authors.initials: D
authors.lastname: Joshua
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D010265:Paraproteinemias / Q000150:complications* / Q000188:drug therapy; D000077211:Zoledronic Acid